All In Biotech

Drug Trial Radar · NCT07061574

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

Apr 15, 2030

Study completion Apr 15, 2031

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jaeb Center for Health Research
First posted
Jul 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

Conditions

  • Type 1 Diabetes
  • New Onset

Interventions

  • Anti-thymocyte globulin (ATG)Drug

    ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.

  • verapamil extended-release capsuleDrug

    Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.

  • AdalimumabDrug

    40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stimulated C-peptide AUCTime frame: Week 104

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California · Not yet recruiting

  • UCSF

    San Francisco, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • University of Buffalo

    Buffalo, New York · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Texas Children's Hospital/Baylor College of Medicine

    Houston, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.